BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Cited by in Crossref: 40] [Cited by in F6Publishing: 56] [Article Influence: 40.0] [Reference Citation Analysis]
Number Citing Articles
1 Abd El-fattah EE, Selim HM. Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. International Immunopharmacology 2022;113:109475. [DOI: 10.1016/j.intimp.2022.109475] [Reference Citation Analysis]
2 Han H, Jin W, Li X. Mesenchymal stem cells-based therapy in liver diseases. Mol Biomed 2022;3:23. [DOI: 10.1186/s43556-022-00088-x] [Reference Citation Analysis]
3 Yang C, Guo Y, Wu Z, Huang J, Xiang B. Comprehensive Analysis of Cuproptosis-Related Genes in Prognosis and Immune Infiltration of Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA Sequencing Data. Cancers 2022;14:5713. [DOI: 10.3390/cancers14225713] [Reference Citation Analysis]
4 Zhang J, Han H, Wang L, Wang W, Yang M, Qin Y. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.988956] [Reference Citation Analysis]
5 Fei X, Liu S, Liu P, Wang X, Zhu C, Hou J, Cai J, Pan Y. Identification and validation of a potential key gene SGOL1 for poor prognosis in hepatocellular carcinoma based on a bioinformatics approach. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1043161] [Reference Citation Analysis]
6 Niu Y, Yang W, Qian H, Sun Y. Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated. Cancer Cell Int 2022;22:341. [DOI: 10.1186/s12935-022-02766-w] [Reference Citation Analysis]
7 Storandt MH, Mahipal A, Tella SH, Kommalapati A, Jin Z. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. JHC 2022;Volume 9:1187-1200. [DOI: 10.2147/jhc.s365002] [Reference Citation Analysis]
8 Rizzo A, Ricci AD, Brandi G. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. JPM 2022;12:1788. [DOI: 10.3390/jpm12111788] [Reference Citation Analysis]
9 Cassese G, Han HS, Lee B, Lee HW, Cho JY, Panaro F, Troisi RI. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World J Hepatol 2022; 14(10): 1862-1874 [DOI: 10.4254/wjh.v14.i10.1862] [Reference Citation Analysis]
10 Li D, Zhao X, Pi X, Wang K, Song D. Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00889-y] [Reference Citation Analysis]
11 Bai J, Tang R, Zhou K, Chang J, Wang H, Zhang Q, Shi J, Sun C. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma. BMC Med Genomics 2022;15:222. [PMID: 36284275 DOI: 10.1186/s12920-022-01380-z] [Reference Citation Analysis]
12 Hassan M, Attia MS, Ali-Eldin Z, El Attar G, Elzallat M, Saad HHK, Isaac A. Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients. Tumour Virus Res 2022;14:200249. [PMID: 36265835 DOI: 10.1016/j.tvr.2022.200249] [Reference Citation Analysis]
13 Mangueira VM, de Sousa TKG, Batista TM, de Abrantes RA, Moura APG, Ferreira RC, de Almeida RN, Braga RM, Leite FC, Medeiros KCDP, Cavalcanti MAT, Moura RO, Silvestre GFG, Batista LM, Sobral MV. A 9-aminoacridine derivative induces growth inhibition of Ehrlich ascites carcinoma cells and antinociceptive effect in mice. Front Pharmacol 2022;13:963736. [DOI: 10.3389/fphar.2022.963736] [Reference Citation Analysis]
14 Wang MQ, Li YP, Xu M, Tian Y, Wu Y, Zhang X, Shi JJ, Dang SS, Jia XL. VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors. World J Gastrointest Oncol 2022; 14(10): 1933-1948 [DOI: 10.4251/wjgo.v14.i10.1933] [Reference Citation Analysis]
15 Kang J, Zheng Z, Li X, Huang T, Rong D, Liu X, Qin M, Wang Y, Kong X, Song J, Lv C, Pan X. Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Cell Int 2022;22:312. [PMID: 36224624 DOI: 10.1186/s12935-022-02735-3] [Reference Citation Analysis]
16 Xu Y, Wang M, Ning S, Yang Z, Zhou L, Xia X. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma. Molecules 2022;27:6786. [DOI: 10.3390/molecules27206786] [Reference Citation Analysis]
17 Guo M, Wang W, Bai W, Bai Z, Chen W, Su Y, Wu J, Solimando AG. Depletion and Reversal of Hepatocellular Carcinoma Inducing CTL through ER Stress-Dependent PERK-CHOP Signaling Pathway. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/6413783] [Reference Citation Analysis]
18 Han Q, Wang M, Dong X, Wei F, Luo Y, Sun X. Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential. Front Immunol 2022;13:985815. [DOI: 10.3389/fimmu.2022.985815] [Reference Citation Analysis]
19 Zhou Q, Wu J, Lian B, Zhang B, Zhang P, Pan R. Glycyrrhetinic Acid-Modified Sulfated Hyaluronic Acid Nanoparticles Coencapsulating Doxorubicin and Magnolol for the Synergistic Treatment of Hepatocellular Carcinoma. ACS Appl Nano Mater . [DOI: 10.1021/acsanm.2c03245] [Reference Citation Analysis]
20 Gao S, Jiang X, Wang L, Jiang S, Luo H, Chen Y, Peng C. The pathogenesis of liver cancer and the therapeutic potential of bioactive substances. Front Pharmacol 2022;13:1029601. [DOI: 10.3389/fphar.2022.1029601] [Reference Citation Analysis]
21 Liu K, Wu J, Xu Y, Li D, Huang S, Mao Y. . OTT 2022;Volume 15:1079-94. [DOI: 10.2147/ott.s383685] [Reference Citation Analysis]
22 Rizzo A, Ricci AD. Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. IJMS 2022;23:11363. [DOI: 10.3390/ijms231911363] [Reference Citation Analysis]
23 Kasprzak A, Adamek A. Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers. IJMS 2022;23:11188. [DOI: 10.3390/ijms231911188] [Reference Citation Analysis]
24 Delangre E, Oppliger E, Berkcan S, Gjorgjieva M, Correia de Sousa M, Foti M. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. IJMS 2022;23:11030. [DOI: 10.3390/ijms231911030] [Reference Citation Analysis]
25 Guo J, Yuan Q, Fang Y, Liao J, Zhang Z. Long non-coding RNA NEAT1 promotes angiogenesis in hepatoma carcinoma via the miR-125a-5p/VEGF pathway. Open Life Sciences 2022;17:1229-39. [DOI: 10.1515/biol-2022-0498] [Reference Citation Analysis]
26 Lu K, Pan Y, Huang Z, Liang H, Ding ZY, Zhang B. TRIM proteins in hepatocellular carcinoma. J Biomed Sci 2022;29:69. [PMID: 36100865 DOI: 10.1186/s12929-022-00854-7] [Reference Citation Analysis]
27 Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
28 Xu J, Wu X, Wang X. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma. Biochem Genet. [DOI: 10.1007/s10528-022-10279-4] [Reference Citation Analysis]
29 Epremyan KK, Goleva TN, Rogov AG, Lavrushkina SV, Zinovkin RA, Zvyagilskaya RA. The First Yarrowia lipolytica Yeast Models Expressing Hepatitis B Virus X Protein: Changes in Mitochondrial Morphology and Functions. Microorganisms 2022;10:1817. [PMID: 36144419 DOI: 10.3390/microorganisms10091817] [Reference Citation Analysis]
30 Xia H, Huang Z, Xu Y, Yam JWP, Cui Y. Reprogramming of central carbon metabolism in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2022;153:113485. [DOI: 10.1016/j.biopha.2022.113485] [Reference Citation Analysis]
31 Chen L, Zhang D, Zheng S, Li X, Gao P. Stemness analysis in hepatocellular carcinoma identifies an extracellular matrix gene–related signature associated with prognosis and therapy response. Front Genet 2022;13:959834. [DOI: 10.3389/fgene.2022.959834] [Reference Citation Analysis]
32 Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, Daneshi S, Salimimoghadam S, Mirzaei S, Hashemi M, Samarghandian S. LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother 2022;154:113609. [PMID: 36037786 DOI: 10.1016/j.biopha.2022.113609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Guizhen Z, Guanchang J, Liwen L, Huifen W, Zhigang R, Ranran S, Zujiang Y. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Front Endocrinol 2022;13:918869. [DOI: 10.3389/fendo.2022.918869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang C, Xu H, Sui X, Wu T, Chen B, Wang S, Wang X, Wang F. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-27. [DOI: 10.1155/2022/7073472] [Reference Citation Analysis]
35 Xu W, Zhao D, Huang X, Zhang M, Yin M, Liu L, Wu H, Weng Z, Xu C. The prognostic value and clinical significance of mitophagy-related genes in hepatocellular carcinoma. Front Genet 2022;13:917584. [DOI: 10.3389/fgene.2022.917584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Marsh-Wakefield F, Ferguson AL, Liu K, Santhakumar C, McCaughan G, Palendira U. Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113270. [PMID: 35898965 DOI: 10.1177/17588359221113270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Fang Y, Su C. Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases. Front Oncol 2022;12:893716. [DOI: 10.3389/fonc.2022.893716] [Reference Citation Analysis]
38 Wei W, Liu C, Wang M, Jiang W, Wang C, Zhang S. Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma. Front Genet 2022;13:906496. [DOI: 10.3389/fgene.2022.906496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 He Q, Yang J, Jin Y. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Brief Bioinform 2022;23:bbac291. [PMID: 35849048 DOI: 10.1093/bib/bbac291] [Reference Citation Analysis]
40 Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:896752. [PMID: 35757756 DOI: 10.3389/fimmu.2022.896752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Xu J, Liu D, Liu Z, Yang J, Chen H. Mechanism of a Herbal Formula Associated with Prognosis and Immune Infiltration in LIHC: Transcriptomics Analysis and Molecular Dynamics Simulations. Evid Based Complement Alternat Med 2022;2022:6084321. [PMID: 35754689 DOI: 10.1155/2022/6084321] [Reference Citation Analysis]
42 Gao X, Jia X, Xu M, Xiang J, Lei J, Li Y, Lu Y, Zuo S. Regulation of Gamma-Aminobutyric Acid Transaminase Expression and Its Clinical Significance in Hepatocellular Carcinoma. Front Oncol 2022;12:879810. [DOI: 10.3389/fonc.2022.879810] [Reference Citation Analysis]
43 Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Pu Z, Liu Z, Chen J, Inoue K, Ruan Z, Zhu L, Kikuchi H, Matsui A, Huang P, Duda DG. Inflammasome targeting with an NLRP3 agonist therapy is feasible but ineffective in murine hepatocellular carcinoma models with liver damage.. [DOI: 10.1101/2022.06.23.497362] [Reference Citation Analysis]
45 Liu Y, Fu B, Yu Z, Song G, Zeng H, Gong Y, Ding Y, Huang D. Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:497-516. [PMID: 35669909 DOI: 10.2147/JHC.S363862] [Reference Citation Analysis]
46 Gao W, Fan X, Bi Y, Zhou Z, Yuan Y. Preparation of NIR-Responsive Gold Nanocages as Efficient Carrier for Controlling Release of EGCG in Anticancer Application. Front Chem 2022;10:926002. [DOI: 10.3389/fchem.2022.926002] [Reference Citation Analysis]
47 Bejjani AC, Finn RS. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations. J Clin Oncol 2022;:JCO2102605. [PMID: 35649192 DOI: 10.1200/JCO.21.02605] [Reference Citation Analysis]
48 Sun X, Xin S, Jin L, Zhang Y, Ye L. Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer. Bioengineered 2022;13:13986-99. [PMID: 35758021 DOI: 10.1080/21655979.2022.2085284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kang SM, Khalil L, El-Rayes BF, Akce M. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Front Oncol 2022;12:821903. [PMID: 35433430 DOI: 10.3389/fonc.2022.821903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhou S, Xu J, Wang D, Wang Y, Meng L, Cao S. Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/5224434] [Reference Citation Analysis]
51 Lai X, Wu Y, Hong G, Li J, Luo Q, Yuan J, Dai G, Liu S, Feng H, Wang F. A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9117205] [Reference Citation Analysis]
52 Wang J, Yang Z, Tang D, Han R, Bi Z, Lin L. GARS is implicated in poor survival and immune infiltration of hepatocellular carcinoma. Cell Signal 2022;:110302. [PMID: 35271987 DOI: 10.1016/j.cellsig.2022.110302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Jin A, Yang Y, Su X, Yang W, Liu T, Chen W, Li T, Ding L, Wang H, Wang B, Pan B, Zhou J, Fan J, Yang X, Guo W. High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Du M, Cai YM, Yin YL, Xiao L, Ji Y. Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections. World J Clin Cases 2022; 10(3): 856-869 [DOI: 10.12998/wjcc.v10.i3.856] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life (Basel) 2021;11:1355. [PMID: 34947886 DOI: 10.3390/life11121355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]